Morepen Laboratories Limited (MOREPENLAB) Price & Analysis

Compare

13 Followers

MOREPENLAB Stock Chart & Stats

₹41.99

-₹1.18(-1.56%)

At close: Jan 08 4:00 PM EST

₹41.99

-₹1.18(-1.56%)

Day’s Range― - ―

52-Week Range₹33.47 - ₹70.40

Previous CloseN/A

Volume3.34M

Average Volume (3M)88.30K

Market Cap

₹20.90B

Enterprise Value₹22.23B

Total Cash (Recent Filing)₹932.86M

Total Debt (Recent Filing)₹1.58B

Price to Earnings (P/E)20.5

Beta1.86

Next Earnings

May 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.49%

Share Statistics

EPS (TTM)0.50

Shares Outstanding547,953,700

10 Day Avg. Volume126,704

30 Day Avg. Volume88,304

Financial Highlights & Ratios

PEG Ratio1.32

Price to Book (P/B)2.29

Price to Sales (P/S)1.45

P/FCF Ratio-28.80

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Strong Capital StructureA very low debt-to-equity ratio (0.09) and a high equity ratio (65%) provide durable financial flexibility, lowering default and refinancing risk. This capital structure supports sustained investment in manufacturing capacity and R&D without excessive interest burden, aiding long-term stability and strategic optionality.

Diversified API And Formulations BusinessOperating both API production and finished formulations across domestic and export markets gives structural revenue diversification. This dual model reduces reliance on single-market demand, enables cross-selling, and leverages manufacturing scale for margin improvement, supporting steadier revenue over multi-quarter horizons.

Healthy Gross And Operating MarginsSustained gross profit of 34.4% and solid EBIT (17.3%) indicate underlying manufacturing efficiency and pricing power in core products. These margin levels provide room to absorb cost inflation, fund incremental capex, and support reinvestment into scale or product development, underpinning medium-term profitability resilience.

Bears Say

Negative Free Cash Flow And Cash ConversionDespite stronger operating cash, negative free cash flow signals that cash generated doesn't cover capex and working capital needs, pressuring liquidity. Over months this can limit capacity to repay liabilities, fund dividends, or invest without external financing, raising structural funding risk if unresolved.

Declining Net Profit MarginA drop in net margin to 6.5% indicates erosion between gross and bottom-line, suggesting rising operating costs, pricing pressure, or higher non-operating expenses. If persistent, margin compression will hinder retained earnings accumulation and limit the firm’s ability to self-fund growth or buffer cyclical downturns over coming quarters.

Earnings Contraction (EPS Decline)A roughly 24% decline in EPS signals material earnings pressure that may reflect product mix shifts, margin weakness, or one-off costs. Persistent EPS contraction constrains retained earnings, weakens return metrics, and can reduce strategic flexibility to invest in new capabilities or pursue higher-margin opportunities long term.

Morepen Laboratories Limited News

Morepen Labs Wins ₹825 Crore Global CDMO Contract From Pharma Major

An update from Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) is now available. Morepen Laboratories has secured an international...

21d ago

Morepen Labs Wins ₹825 Crore Global CDMO Mandate to Scale Manufacturing Platform

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) has shared an update. Morepen Laboratories has secured a multi-year CDMO mandate...

22d ago

Morepen Labs Reports Minimal Activity in SEBI Special Window for Physical Share Transfers

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) just unveiled an announcement. Morepen Laboratories has reported to the stock exchanges...

2M ago

Morepen Laboratories Reports No Share Transfer Activity in November 2025

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) has issued an update. Morepen Laboratories Limited reported to the stock exchanges...

4M ago

Morepen Laboratories Releases Financial Results for September 2025

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) just unveiled an announcement. Morepen Laboratories Limited has announced the publication of...

4M ago

Morepen Laboratories Subsidiary Forms Joint Venture in Medical Devices

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) has issued an announcement. Morepen Laboratories Limited announced that its subsidiary, Morepen...

6M ago

MOREPENLAB FAQ

What was Morepen Laboratories Limited’s price range in the past 12 months?

Morepen Laboratories Limited lowest stock price was ₹33.47 and its highest was ₹70.40 in the past 12 months.

What is Morepen Laboratories Limited’s market cap?

Morepen Laboratories Limited’s market cap is ₹20.90B.

When is Morepen Laboratories Limited’s upcoming earnings report date?

Morepen Laboratories Limited’s upcoming earnings report date is May 06, 2026 which is in 51 days.

How were Morepen Laboratories Limited’s earnings last quarter?

Morepen Laboratories Limited released its earnings results on Feb 10, 2026. The company reported ₹0.502 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.502.

Is Morepen Laboratories Limited overvalued?

According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Morepen Laboratories Limited pay dividends?

Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.49%. See more information on Morepen Laboratories Limited dividends here

What is Morepen Laboratories Limited’s EPS estimate?

Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Morepen Laboratories Limited have?

Morepen Laboratories Limited has 547,953,700 shares outstanding.

What happened to Morepen Laboratories Limited’s price movement after its last earnings report?

Morepen Laboratories Limited reported an EPS of ₹0.502 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.24%.

Which hedge fund is a major shareholder of Morepen Laboratories Limited?

Currently, no hedge funds are holding shares in IN:MOREPENLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Morepen Laboratories Limited

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.